Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Aleva Neurotherapeutics, a Switzerland-based developer of deep neurological implants founded on EPFL research, has received $8m from undisclosed investors in the inaugural close of its ongoing series E round. The spinout has secured European market approval for an electrode-powered deep brain stimulation device for indications such as Parkinson’s and essential tremour, and will now pursue…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.